Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
5.63
+0.13 (2.46%)
Mar 17, 2026, 10:48 AM EDT - Market open
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$670,908
Profits / Employee
$1,274
Market Cap
969.93M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 700 |
| Pharming Group | 404 |
| UroGen Pharma | 291 |
| uniQure | 221 |
| Inhibrx Biosciences | 161 |
| Sana Biotechnology | 142 |
| Adlai Nortye | 123 |
| GH Research | 50 |
XERS News
- 5 days ago - Xeris Biopharma Holdings, Inc. (XERS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 14 days ago - Xeris Biopharma Holdings, Inc. (XERS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance - Business Wire
- 17 days ago - Why Are Shares Of Xeris Biopharma Falling Friday? - Benzinga
- 18 days ago - Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit - Business Wire
- 4 weeks ago - Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 - Business Wire
- 6 weeks ago - Xeris Biopharma: Strong Recorlev Momentum And Pipeline Opportunity - Seeking Alpha
- 2 months ago - Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue - Business Wire